Chemours Q2 sales flat as lower volumes weigh on results
CC•Outlook and key figures
- Chemours expects Q3 adjusted EBITDA between $175 mln and $205 mln
- Company maintains 2026 adjusted EBITDA outlook of $775 mln to $825 mln
- Chemours sees 2026 net sales growing 1% to 5% over 2025
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Sales | Miss | $1.60 bln | $1.65 bln (7 Analysts) |
| Q2 Adjusted EPS | Meet | $0.42 | $0.42 (9 Analysts) |
| Q2 Loss Per Share | $1.81 | ||
| Q2 Adjusted Net Income | Beat | $64 mln | $60.68 mln (6 Analysts) |
| Q2 Adjusted EBITDA | Beat | $247 mln | $238.07 mln (8 Analysts) |
Quarterly results and drivers
-
US industrial chemicals maker's Q2 sales were flat yr/yr and missed analyst expectations
-
Adjusted EPS for Q2 met analyst expectations
-
Adjusted net income and adjusted EBITDA for Q2 beat analyst estimates
-
VOLUME DECLINES - Co said lower volumes, particularly in TSS aftermarket refrigerants and APM due to a line closure, weighed on sales
